With long term, low-to-moderate dose methotrexate therapy, elevations in serum ALT or AST values occur in 15 to 50% of patients, but are usually mild and self-limiting. Approximately 5% of patients have elevations greater than twice normal and these abnormalities resolve rapidly with discontinuation or dose modification, but can resolve even with continuation at the same dose level.